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Background: Diagnostic testing to antibiotics other than to penicillin has not been widely available, making the
diagnosis of antibiotic allergy difficult and often erroneous. There is often reluctance in performing challenges to
antibiotics when standardized testing is lacking. However, while the immunogenic determinants are not known for
most antibiotics, a skin reaction at a non-irritating concentration (NIC) may mean that antibodies to the native form
are present in the circulation. While the NIC’s for many non penicillin antibiotics have been determined in adults,
the use of these concentrations for skin testing pediatric subjects prior to provocative challenge has not been
done. Our objective was to determine if we could successfully uncover the true nature of antibiotic allergy in
children using these concentrations for testing.
Methods: Children were included between 2003–2009 upon being referred to the Drug and Adverse Reaction/
Toxicology (DART) clinic of the Hospital for Sick Children in Toronto, Ontario Canada. The referral needed to
demonstrate that clinical care was being compromised by the limitation in antibiotic options or there was a
significant medical condition for which the label of antibiotic allergy may prove detrimental. Patients were not seen
if there was a suggestion of serum like sickness, Stevens Johnson Syndrome or Toxic Epidermal Necrolysis. Patients
were excluded from testing if there was objective evidence of anaphylaxis. All other patients were consented to
receive testing and/or challenges. A retrospective chart review was then performed of the results.
Results: We were able to exclude an antibiotic allergy in the majority of our patients who had a negative
intradermal test result and were then challenged (>90%). Only one patient was challenged with a positive
intradermal test to Cotrimoxazole because of a questionable history and this patient failed the provocative
challenge. While we did not challenge more patients with positive testing, we did note that 10/11 (91%) patients
with positive intradermal testing had some aspect of a Type 1 reaction in their history.
Conclusions: Through testing with NIC’s of various antibiotics in children and providing provocative challenges
based on negative skin testing results, we were able to advance the medical care of the majority of our patients by
increasing their antibiotic options in order to successfully treat future infections. While challenging patients with
positive testing was not deemed ethically appropriate at this stage of our study, it would be a useful future step to
reaching statistical validity of testing to these antibiotics.
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Cotrimoxazole 80 0.8 12 20.3%
Ceftriaxone 100 10 8 13.6%
Cefuroxime 100 10 7 11.9%
Clindamycin 150 15 7 11.9%
Cefazolin 330 33 6 10.2%
Ceftazidime 100 10 5 8.5%
Azithromycin 100 0.01 5 8.5%
Erythromycin 50 0.05 3 5.1%
Aminoglycoside 40 4 2 3.4%
Vancomycin 50 0.005 2 3.4%
Levofloxacin 25 0.025 2 3.4%
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The label of drug allergy is a commonly encountered
problem in medical practice. As documented with
penicillin allergy, the accuracy of such labels is often
poor and the vast majority is actually not allergic to
the antibiotic in question [1-3]. If the individual is
most often well and the sensitivity profile of the par-
ticular microorganism is expansive, these drug allergy
labels may not prove detrimental to successfully
treating an infection. Elucidating the precise nature of
the drug allergy label becomes more critical in the
case of a complex medical condition predisposing to
recurring infections, multiple drug allergy or when
targeting an organism with a very narrow sensitivity
profile. Certainly in an era where multiple drug resist-
ant strains of bacteria (so called ‘superbugs’) have
caused outbreaks of deleterious infection, a label of
just one antibiotic allergy may become relevant even
for otherwise healthy individuals.
Unfortunately, standardized drug allergy testing is
only available commercially for penicillin because the
clinically relevant metabolic byproducts are known.
Even in this case, it is difficult to obtain a mixture of
minor determinants which can cause a substantial
proportion of reactions. Not knowing the metabolic
determinants that are clinically relevant for other an-
tibiotics has been a limiting factor in the production
of testing materials. Furthermore, the concentration
of antibiotic that is appropriate for triggering an IgE
mediated reaction and not an irritative reaction dur-
ing skin testing has been a subject of debate and one
that has limited the scope of antibiotic allergy testing.
However, Empedrad et al., through sequentially test-
ing various concentrations of certain non penicillin
antibiotics in adults, were able to determine many
non-irritating concentrations (NIC’s) [4]. Ultimately,
however, drug provocation is the gold standard in de-
finitively excluding an IgE mediated reaction to the
drug [5]. The reassurance of negative skin testing
prior to a provocation can be profound both for pa-
tients and for health practitioners who must justify
readministration of these medications [1,3,5]. Since
these particular NIC’s used in adults (Table 1) had
never been trialed in children prior to a provocative
challenge, we hypothesized that the NICs would likely
be similar in the younger population. In this scenario,
we believed it would be a useful tool to help decide
which patients would be suitable to proceed to a drug
challenge. We believed that the impact in a tertiary
or quaternary care centre in terms of expanding
treatment options for complex patients had the po-
tential of being significant and worth the risk of a re-
action during a challenge if patients were chosen
carefully.Methods
Our study was approved through the Research and
Ethics Board of the Hospital for Sick Children. Visits
to our Drug Adverse Reaction and Toxicology (DART)
clinic were screened between 2004–2009 for a history
of possible allergy to various antibiotics. Since this was
only meant as an introductory study, we accepted chil-
dren up to 18 years of age into our clinic if the referral
demonstrated that the patient had a complex medical
condition predisposing to multiple infections, if med-
ical treatment was significantly compromised by the
limitation in antibiotic options or if there was limited
organism sensitivity. Table 2 outlines the range of dis-
orders found in our cohort. We believed that the clin-
ical impact during this introductory phase of our study
was highest for these patients. Healthy children not ex-
periencing frequent infections were typically not even
brought to the clinic even if referred. Also, if the refer-
ral was even remotely suggestive of serum like sick-
ness, Stevens Johnsons Syndrome or Toxic Epidermal
Necrolysis, the patient was not brought to clinic.
During the initial visit, each patient and their family
were interviewed with a standard questionnaire that was
meant to extract the type of antibiotic that caused the
reaction and the indication for its administration. A de-
tailed history around the reaction to the medication was
elicited and past medical and pharmacy records were
reviewed in detail to minimize recall bias. We also
strived to appreciate how challenging it subsequently be-
came to treat that particular infection or future infec-
tions. For example, if a cystic fibrosis patient became
labeled with a Ceftazidime allergy, there would be a limi-
tation on treating Pseudomonas infections which cause
significant morbidity and mortality in this population.
Patients were excluded from proceeding with testing if
there was a very clear history of anaphylaxis as
Table 2 Medical conditions of patients included for
testing
Limited treatment options/Reaction to multiple
antibiotics
12 (28.6%)









End Stage Renal Disease 6 (14.3%)
Muskoloskeletal Infection/Foreign Body 5 (11.9%)
Severe ureteric reflux 2 (4.8%)
Spina Bifida 1 (2.3%)
Malignancy 1 (2.3%)
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rated by medical records. The selected patients were
skin tested with NICs published for adults by Empedrad
et al. and outlined in Table 1 [4]. Histamine was the
positive control for skin prick testing and 0.9% saline
was the negative control for both skin prick and intra-
dermal testing. A provocative challenge with the anti-
biotic was offered in either the oral or intravenous form
if intradermal testing was negative or if there was suffi-
cient doubt about a positive result. Patients were in gen-
eral not challenged if they had a positive intradermal
test during this phase of our study. Due to the young
age of some of our patients who would have a limited
ability to articulate the onset of severe adverse symp-
toms, our ethics board believed that the level of risk was
too high to administer medications in this setting.Results
We examined a total of 47 patients in our clinic and 42
were included in the study. The five that were excluded
had a history very convincing for true anaphylaxis and
had alternatives for treatment. The medications they
reacted to included Ceftriaxone (3 patients) and
Cefuroxime (2 patients). Some patients were seen for
testing to more than one antibiotic making the total
number of visits 59. For a summary of the patients’
medical conditions and results, please refer to Table 2
and Figure 1.
At all 59 visits skin prick testing was performed. Only
one patient had positive skin prick testing. This patient
had a history of possible anaphylaxis with Ceftriaxone
administration and was therefore not tested via theintradermal route. On 57/59 (96.6%) visits, intradermal
testing was performed. One other patient did not have
intradermal testing because behaviour did not permit
this to be done safely.
46/57 visits (80.7%) tested with the intradermal
method had negative testing while 11 were positive
(19.3%). The majority of the latter, 10/11 (91%), had a
history consistent with an immediate IgE mediated reac-
tion either to the antibiotic in question or to an anti-
biotic in the same class. The majority of the positive
tests were accounted for by a history of sensitivity to
Cotrimoxazole, 6/11 (54.5%). One patient had sensitivity
to Erythromycin, 1 to Vancomycin, 1 to Ceftriaxone and
2 to Azithromycin.
42 of the 46 patients (91.3%) with negative intradermal
testing went on to receive an oral challenge with the
antibiotic that was tested. Attempts were made to chal-
lenge the other 4 patients with negative testing but they
did not show to their challenge appointments and were
lost to follow up. One patient with positive intradermal
testing to Cotrimoxazole was challenged due to an un-
usual history of only hypotension with the medication. It
was thought that perhaps sepsis may have been the
cause of his hypotension with the initial administration.
Another challenge was done with parental consent with-
out intradermal testing because of aggressive patient
behaviour.
Of the 44 total challenges performed, 40 were success-
ful (90.9%) after a one hour observation period and did
not have a delayed reaction after being discharged. 39/42
(92.9%) of patients with negative intradermal skin testing
tolerated the medication.
The 4 failed challenges including the patient with
positive intradermal testing to Cotrimoxazole. The
other 3 patients failed despite a negative intradermal
test. However, in their referral histories, one had hives
with Tobramycin, and another had vomiting and
pharyngeal pruritus with Ceftriaxone. The third had a
maculopapular rash in the referral history but had urti-
caria 4 days after our challenge to Cefuroxime.
23 patients experienced hives without anaphylaxis in
the original history. All had negative skin prick testing.
However, 18/23 (78.3%) had negative intradermal testing
and 5 patients (21.7%) tested positive. 17 of the 18 pa-
tients with negative intradermal testing were challenged.
One patient did not come to the challenge appointment.
16/17 (94.1%) of those with negative skin testing but ur-
ticaria in the history passed the challenge.
Alternatively, the majority of patients with a history of
possible anaphylaxis tested positive. 4/6 (66.7%) had
positive skin testing and 1 with negative testing failed a
provocative challenge. The other patient with negative
testing to Ceftriaxone did not appear for the provocative
challenge.
Figure 1 Summary of results of patient testing and challenges.
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other than in the referral history in order to give the pa-
tient a treatment option. 9 of these patients were tested
to an antibiotic in a different class and tolerated the
challenge. 6 patients were tested with an antibiotic in
the same class and 2 of these patients had positive intra-
dermal testing (1 cephalosporin and 1 macrolide). Theremaining 4/6 patients tolerated the challenge to an
antibiotic in the same class.
Discussion
NIC’s for testing to a limited list of antibiotics have been
validated in adults [4]. We believed that testing with
these concentrations could be a useful decision making
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finitively characterize antibiotic allergies in our pediatric
patients. While standardized testing to a wide range of
antibiotics is lacking, elucidating antibiotic allergies in
the pediatric population can have a major clinical impact
as this population tends to experience a high burden of
infectious diseases while their immune systems mature.
The vast majority (10/11, 90.9%) of our patients who
had positive testing also had a history of an immediate
IgE mediated reaction such as urticaria. Over 90% of
those with negative skin testing were able to tolerate a
provocative challenge to the medication. Since we used
the intact antibiotic for testing rather than metabolites,
our promising findings suggest that there may in fact be
IgE antibodies to the native drug itself rather than only
to immunogenic determinants or unique haptens formed
after metabolism as previously thought [1,4]. We were
able to improve the care of patients with chronic med-
ical conditions by uncovering falsely diagnosed allergy to
antibiotics. In the case of cystic fibrosis patients, having
an expanded repertoire of antibiotics to treat aggressive
organisms such as Pseudomonas could prove life alter-
ing. Treating febrile neutropenia with the least toxic
regimen of antibiotics may also make a significant differ-
ence to clinical outcome in a cancer patient. Further-
more, we have demonstrated that using only a history of
minor acute Type 1 mediated symptoms may not be ad-
equate to diagnose antibiotic allergy. In penicillin testing,
the history has been found to be poorly predictive of
subsequent skin test results [3,6-8]. Symptoms such as
urticaria may be triggered by other causes such as the
underlying infection itself [9]. In our study, most pa-
tients with urticaria alone who did not have associated
anaphylactic symptoms had negative testing and passed
the provocative challenge.
A significant limitation of our study is that we did not
challenge patients with urticaria in the history who had
positive skin testing. This would certainly have given
greater impact to the meaning of a positive test and
would have allowed us to be even more confident that a
positive result is not merely an irritative effect in a child.
While we are at ease in our clinic with the caution and
technique we use when challenging patients that have a
higher risk of reacting, we could not obtain ethics ap-
proval for testing all children with positive testing. Now
that our outcomes of challenges with negative testing
are favourable in the sense that we did not substantially
under identify the number of truly allergic children, we
hope to obtain permission to challenge all patients, re-
gardless of test result in the future. We also recognize
that the numbers of children tested to each antibiotic
were relatively low and we hope to significantly increase
these numbers going forward. Furthermore, we have as-
sumed that the NIC’s shown in adults are transferable tochildren. Verifying this further would require intrader-
mal testing children to multiple concentrations and
performing the same on controls without a history of
drug allergy. Convincing parents to consent to intrader-
mal testing multiple times when they may already be
struggling with a chronically ill and needle phobic child
would be a difficult task and one that our ethics board
was not open to entertaining.
Conclusions
Skin testing to multiple different antibiotics in their na-
tive form in children can potentially be a reliable, object-
ive guide to successful challenges. In a tertiary or
quaternary care centre, an allergy service that is willing
to take on the risk involved in challenging patients with
a wide array of antibiotics that may have caused a reac-
tion in the past can make a significant contribution to
the care of complex patients.
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